Targeting of constitutively active survival pathways such as NFκB with agents such as TQ in cancer allow selective killing of these aggressive cells with minimal targeting of their normal counterparts thereby decreasing the chances of toxicity. The gene discussed is NFKB1; the disease is cancer.